A Phase 2 interventional study of SNA-120 and Vehicle in Pruritus and Psoriasis Vulgaris, sponsored by Sienna Biopharmaceuticals. Completed at 38 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-02-08.
Sponsored by Sienna Biopharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies in Pruritus with a site in United States — 24 open to participants now, 28 under way, 8 of them phase 3. Pruritus · United States.
Among the 163 studies in Pruritus with a site in United States, this one is the 42nd largest by enrollment of the 153 interventional ones that give a count, is one of 11 that started in 2017, is one of 60 in phase 2, and was the 66th registered.
491 studies on the registry are indexed under Pruritus; 94 are open to participants now.
Browse Pruritus studies →24 of the 163 studies in Pruritus with a site in United States are open now. Recruiting first, the newest first:
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Novartis Pharmaceuticals · Sites in United States, Canada, China
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Argentina, Canada and 2 more countries
Ages 18+
Paradigm Therapeutics · Sites in United States
Ages 28 days–12 yrs
Integrative Skin Science and Research · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 69 · Phase 3 48 · Phase 4 13
First in 2000; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 208 is above the median of 60 across 423 interventional studies indexed under Pruritus.
Median enrollment 70 across the 153 interventional studies, 80 across the 9 observational. Of the 126 that completed or were terminated, 80 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
108 of 163 have an industry lead sponsor. The 10 most frequent:
Sienna Biopharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.
Sienna Biopharmaceuticals has 2 studies filed under Pruritus — fewer than ten, so there is no comparison to draw.
12 of the studies in Pruritus with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482787Phase 3Paradigm TherapeuticsEfficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | 2027-05-17 |
| NCT05263206Phase 3SanofiEfficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) | 2027-06-02 |
| NCT07450716Massachusetts General HospitalAssessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus | 2026-12 |
| NCT07317271Johns Hopkins UniversityVR-PMR for Post-Burn Symptoms | 2026-12 |
| NCT07074977Galderma R&DProof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO) | 2026-12 |
Add all 12 to your calendar (.ics) → With an account.
Among the 163 studies in Pruritus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To characterize the efficacy, safety and tolerability of SNA-120 at 2 doses versus placebo when administered topically for the treatment of pruritus associated with psoriasis vulgaris (PV) and PV itself.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pegcantratinib Ointment
Drug: SNA-120
Pegcantratinib Ointment
Drug: SNA-120
Drug: Vehicle
Pegcantratinib ointment
Placebo ointment to mimic Pegcantratinib ointment
Change in Itch Numeric Rating Scale scores (I-NRS)
The I-NRS is a 11 point scale, where "0" represents no itch and "10" represents worst possible itching
Time frame: week 1
Change in Itch Numeric Rating Scale scores (I-NRS)
The I-NRS is a 11 point scale, where "0" represents no itch and "10" represents worst possible itching
Time frame: week 2
Change in Itch Numeric Rating Scale scores (I-NRS)
The I-NRS is a 11 point scale, where "0" represents no itch and "10" represents worst possible itching
Time frame: week 4
Change in Itch Numeric Rating Scale scores (I-NRS)
The I-NRS is a 11 point scale, where "0" represents no itch and "10" represents worst possible itching
Time frame: week 6
Change in Itch Numeric Rating Scale scores (I-NRS)
The I-NRS is a 11 point scale, where "0" represents no itch and "10" represents worst possible itching
Time frame: week 8
Proportion of subjects (≥ 1 grade change) on IGA scale
Investigator Global Assessment
Time frame: week 12
Proportion of subjects (≥ 2 grade change) on IGA scale
Investigator Global Assessment
Time frame: week 12
Proportion of subjects categorized as a "0" or "1" on IGA scale and minimum improvement of 2 categories
Investigator Global Assessment
Time frame: baseline and week 12
Change in PASI-50
Percentage of subjects with 50% reductions in Psoriasis Area and Severity Index
Time frame: baseline and week 12
Safety measured by incidence and severity of adverse events
Time frame: up to 12 weeks
Safety measured by change in clinical laboratory results from baseline
urinalysis lab assessments
Time frame: up to 12 weeks
Safety measured by change in clinical laboratory results from baseline
biochemistry lab assessments
Time frame: up to 12 weeks
Safety measured by change in clinical laboratory results from baseline
hematology lab assessments
Time frame: up to 12 weeks
Safety measured by change in blood pressure from baseline
systolic/diastolic blood pressure (BP in mmHg)
Time frame: up to 12 weeks
Safety measured by change in pulse from baseline
Pulse (beats per minute \[bpm\])
Time frame: up to 12 weeks
Safety measured by number of abnormal physical examination changes
Any abnormal physical examination changes from baseline and week 12
Time frame: baseline and week 12
Safety measured by PR/PQ intervals measured by 12-lead ECG
Time frame: week 2
Safety measured by PR/PQ intervals measured by 12-lead ECG
Time frame: week 8
Safety measured by PR/PQ intervals measured by 12-lead ECG
Time frame: week 12
Safety measured by QRS duration measured by 12-lead ECG
Time frame: week 2
Safety measured by QRS duration measured by 12-lead ECG
Time frame: week 8
Safety measured by QRS duration measured by 12-lead ECG
Time frame: week 12
Safety measured by QT interval measure by 12-lead ECG
Time frame: week 2
Safety measured by QT interval measure by 12-lead ECG
Time frame: week 8
Safety measured by QT interval measure by 12-lead ECG
Time frame: week 12
Ran from Oct 2017 to primary completion in Sep 2018, 11 months.
Of 37 industry-sponsored phase 2 interventional studies under Pruritus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's 11 months is below that.
Counting every sponsor, half of 52 studies reached it within 16 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegcantratinib
Sienna Biopharmaceuticals